ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 11

Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome

Alonso Turrent1, Gabriela Hernandez-Molina2 and Antonio R. Cabral3, 1Immunology and Rheumatology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Anticoagulation, Antiphospholipid syndrome and thrombosis

  • Tweet
  • Email
  • Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: The current recommended anti-thrombotic therapy for patients with anti-phospholipid syndrome (APS) is oral anticoagulants with an INR intensity between 2-3. This recommendation has been mostly derived from retrospective and prospective randomized studies based on INRs determined at time of thrombosis or the closest available one.  The current recommended anti-thrombotic therapy for patients with anti-phospholipid syndrome (APS) is oral anticoagulants with an INR intensity between 2-3. This recommendation has been mostly derived from retrospective and prospective randomized studies based on INRs determined at time of thrombosis or the closest available one. Objective: To evaluate the rate of re-thrombosis in patients with primary APS (PAPS) during a defined anticoagulation index period.

Methods: We studied patients attending a Tertiary Referral Care Center according to the following inclusion criteria: PAPS (Sydney Criteria), a history of one or more episodes of thrombosis, on oral anticoagulants and ≥2 INR determinations per year. Index period was defined as either the time elapsed between the first available INR and the next thrombotic event or the time between the first and last available INRs in rethrombosis-free patients. We also analyzed the number of thrombotic episodes before the index period. Statistical analysis:  We used X2 test, U-Mann Whitney test and Cox survival analysis.

Results: We studied 81 PAPS patients (73% women) with a mean age of 46.8 ± 15.5 years and a median follow-up of 6.4 years (range 0.15-17). Sixty-four patients did not have an episode of re-thrombosis, while 17 had a new episode of thrombosis during follow-up. The latter by definition was longer in thrombotic-free patients (6.7 vs. 1.9 years, p= 0.003). The median INR during the anticoagulation index period was significantly higher in re-thrombosis-free patients (2.5, 1.1-3.6) compared with patients with recurrent thrombosis (1.9, 1-2.9, p=0.001). The median number of INR determinations per years of follow-up was similar in both groups (4.9 vs. 5.7). The number of thrombotic episodes in re-thrombosis-free patients before the index period (1, 1-4) was lower compared with their re-thrombosed counterparts (3, 1-5, p<0.001). Both differences remained statistically different after Cox analysis (median INR: OR 0.13, 95% CI: 0.05-0.32, p<0.001; history of rethrombosis: OR 17.4 (2.2-133.8, p=0.006). No differences were found between the two groups in the frequencies of ant-cardiolipin (IgG or IgM), anti-b2-glycoprotein-I (IgG or IgM), lupus anticoagulant, triple marker positivity, dyslipidemia, cigarette consumption, aspirin and immunosuppressive therapy, arterial hypertension and diabetes mellitus.

Conclusion: A sustained INR of 2.5 for secondary thromboprophylaxis in patients with PAPS appears to be protective whereas a previous thrombosis confers risk. PAPS patients were more prone to develop recurrent thrombosis if their INR persistently remained beneath that threshold during follow-up.


Disclosure:

A. Turrent,
None;

G. Hernandez-Molina,
None;

A. R. Cabral,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sustained-moderate-intensity-levels-of-oral-anticoagulant-therapy-and-the-rate-of-recurrent-thrombosis-in-patients-with-primary-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology